Welcome to the international HTA database

Showing [22159 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	Institute for Clinical and Economic Review (ICER)	Fezolinetant for moderate to severe vasomotor symptoms associated with menopause: effectiveness and value
2023	NIHR Health Technology Assessment programme	Techniques to increase lumbar puncture success in newborn babies: the NeoCLEAR RCT
2023	Ontario Health	Wire-free, nonradioactive localization techniques to guide surgical excision of nonpalpable breast cancer tumours
2023	Ontario Health	Placental growth factor (PlGF)-based biomarkers for risk prediction in people with suspected preeclampsia
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Image-guided spinal injections in the treatment of chronic spinal pain: an overview of evidence-based guideline recommendations and specific focus on guidance techniques
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Robot-assisted rehabilitation for incomplete spinal cord injury]
2023	Institute for Clinical and Economic Review (ICER)	Gene therapies for sickle cell disease: effectiveness and value
2023	Austrian Institute for Health Technology Assessment (AIHTA)	SMA therapies: mid- to long-term follow-up of spinal muscular atrophy (SMA) patients treated for ≥24 months with nusinersen or onasemnogene abeparvovec and ≥12 months for patients treated with risdiplam or combination therapies
2023	Institute for Clinical and Economic Review (ICER)	Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH)
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Strategies for recruitment and programme adherence in group programmes for children, adolescents and adults with overweight and grade 1 obesity]
2023	Institute for Clinical and Economic Review (ICER)	Lecanemab for early Alzheimer’s disease
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Myopia control spectacle lenses for children and adolescents]
2023	Institute for Clinical and Economic Review (ICER)	Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Registries in Austria and their utilisation for healthcare improvement]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Autologous fat grafting in osteoarthritis]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Endovenous laser therapy for varicose veins in the lower extremities]
2023	NIHR Health Technology Assessment programme	Views of female genital mutilation survivors, men and health-care professionals on timing of deinfibulation surgery and NHS service provision: qualitative FGM Sister Study
2023	Institute for Clinical and Economic Review (ICER)	Value assessment framework
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fibromatoses of the hand (Dupuytren's disease) and / or foot (Ledderhose's disease): do those affected benefit from radiation therapy?]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Effectiveness and safety of coronary sinus narrowing device for the treatment of refractory angina]
2023	Institute for Clinical and Economic Review (ICER)	ICER-PHTI assessment framework for digital health technologies
2023	Institute for Clinical and Economic Review (ICER)	White bagging, brown bagging, and site of service policies: best practices in addressing provider markup in the commercial insurance market
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Restless legs syndrome: can the symptoms be alleviated through non-medicinal procedures?]
2023	Institute for Clinical and Economic Review (ICER)	Applying the results of comparative effectiveness research to control drug costs: policy options for California
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Contraception: comparison of hormonal coils and copper coils]
2023	Norwegian Institute of Public Health (NIPH)	177Lu-PSMA-617 for treatment of metastatic castration resistant prostate cancer: a health technology assessment
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Evaluation of the lung cancer screening program]
2023	Institute for Clinical and Economic Review (ICER)	Advancing health technology assessment methods that support health equity
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Ovarian tissue cryopreservation and transplantation in patients with cancer or benign diseases to fertility preservation]
2023	Institute for Clinical and Economic Review (ICER)	Assessment of barriers to fair access
2023	National Evidence-based Healthcare Collaborating Agency (NECA)	[Low-level light therapy for primary dysmenorrhea]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Efficacy and safety of Emotional Freedom Techniques for the treatment of anxiety, depression and post traumatic stress disorders]
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Effectiveness of communication strategies for patients who are non-vocal due to artificial airways
2023	Health Technology Wales (HTW)	Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Invasive monitoring of pulmonary artery pressure in patients with symptomatic heart failure]
2023	Health Information and Quality Authority (HIQA)	Rapid health technology assessment of continuous glucose monitoring in adults with type 1 diabetes mellitus
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Robotic surgery in benign and malignant surgical pathology (urology, general and digestive surgery, cardiothoracic surgery, gynecology, endocrinology, ophthalmology, and head and neck surgery). Chapter I: cardiothoracic, endocrine, ophthalmological surgery, and head and neck surgery]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Early detection tools for emotional distress in adult people with cancer]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Robotic surgery in benign and malignant surgical pathology (urology, general and digestive surgery, cardiothoracic surgery, gynecology, endocrinology, ophthalmology, and head and neck surgery). Chapter II: urological, gynecological, general and digestive surgery]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Spinal cord stimulation in refractory neuropathic pain in adults: evaluation of efficacy, effectiveness, safety, and efficiency in painful diabetic neuropathy and failed back surgery and complex regional pain syndromes]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of the safety, diagnostic validity, and clinical effectiveness of transcutaneous measurement of partial pressure of oxygen in the management of diabetic foot]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of early intervention programs in psychosis for adolescents and young adults]
2023	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	Assessment of hip protectors for users at risk of falls
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Artificial intelligence for the detection of colorectal precancerous lesions in colonoscopy]
2023	Andalusian Health Technology Assessment Area (AETSA)	[Appropiate indication for leadless pacemaker. Systematic review and appropriateness criteria]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Blood test for the identification and location of different types of cancer]
2023	The Regional Health Technology Assessment Centre (HTA-centrum)	General psychiatric management for patients with personality disorder and/or self-harm behaviour
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: update of the tool for choosing the dosage of monoclonal antibodies targeting PD 1 or PD-L1]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Safety, efficacy, and economic evaluation of the implementation of an abdominal aortic aneurysm screening program]
2023	The Regional Health Technology Assessment Centre (HTA-centrum)	Efficacy and safety of advanced hybrid closed loop systems compared with multiple daily injections or open loop systems, in adults with type 1 diabetes
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Birch Bark Extract (treatment of wounds associated with epidermolysis bullosa (6 months and older))]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[PCR type nucleic acid amplification tests in blood applied to rapid etiological diagnosis in suspected sepsis: assessment of its diagnostic and prognostic utility, safety, and economic and organizational implementation considerations]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Efgartigimod alfa (Myasthenia Gravis, AChR-antibody+)]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Remote monitoring of lung function through self-administered spirometry in patients with asthma, chronic obstructive pulmonary disease or cystic fibrosis: evaluation of safety, clinical efficacy and implementation aspects]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Peripheral electrical nerve stimulation (PENS) therapy as treatment for refractory chronic neuropathic pain in adults: evaluation of safety, efficacy, clinical effectiveness, and cost-effectiveness]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for glutaric acidemia type 1 (GA1)]
2023	Health Technology Wales (HTW)	Solution-focused assessment tools for improving the treatment of people with psychosis and schizophrenia within secondary mental health services
2023	The Regional Health Technology Assessment Centre (HTA-centrum)	[Remote patient monitoring– an overview of systematic reviews for selected diagnosis groups]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for for long-chain acyl-CoA dehydrogenase deficiency (LCHADD) and mitochondrial trifunctional protein deficiency (TFPD)]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Health technology assessment framework: adaptation for digital health technology assessment]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2023	NIHR Health and Social Care Delivery Program	Rapid evaluation of service innovations in health and social care: key considerations
2023	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Update: Functioning and disability - An evidence map]
2023	NIHR Health Services and Delivery Research programme	A rapid mixed-methods evaluation of remote home monitoring models during the COVID-19 pandemic in England
2023	NIHR Health Services and Delivery Research programme	What happens after an NHS Health Check? A survey and realist review
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Non-invasive monitoring of intracranial compliance and intracranial pressure in central nervous system lesions]
2023	NIHR Health Services and Delivery Research programme	Identifying models of care to improve outcomes for older people with urgent care needs: a mixed methods approach to develop a system dynamics model
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Angioplasty and stenting in patients with carotid artery stenosis]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Biomarkers in Alzheimer's disease
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Lecanemab in Alzheimer’s Disease]
2023	NIHR Health Services and Delivery Research programme	Explanation of context, mechanisms and outcomes in adult community mental health crisis care: the MH-CREST realist evidence synthesis
2023	Belgian Health Care Knowledge Centre (KCE)	Silicone adhesive multilayer foam dressings to prevent hospital-acquired pressure ulcers: a Belgian RCT-based economic evaluation
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Mobile cardiopulmonary exercise test in athletes or cardiopulmonary rehabilitation]
2023	NIHR Health Services and Delivery Research programme	Integration, effectiveness and costs of different models of primary health care provision for people who are homeless: an evaluation study
2023	Norwegian Institute of Public Health (NIPH)	Treatments for relapsing and/or refractory multiple myeloma. A health technology assessment
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Lipogems® System for autologous adipose tissue-derived mesenchymal stem cells transfer in orthopedic conditions]
2023	NIHR Health Services and Delivery Research programme	Vertical integration of general practices with acute hospitals in England: rapid impact evaluation
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: use of platelet-rich plasma for the treatment of knee osteoarthritis]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Holmium laser in non-prostate endourologic conditions]
2023	NIHR Health Technology Assessment programme	Frenotomy with breastfeeding support versus breastfeeding support alone for infants with tongue-tie and breastfeeding difficulties: the FROSTTIE RCT
2023	NIHR Health Technology Assessment programme	Motivational support intervention to reduce smoking and increase physical activity in smokers not ready to quit: the TARS RCT
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Sapropterin in patients with phenylketonuria]
2023	NIHR Health Technology Assessment programme	A randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery for open globe trauma – the ASCOT study
2023	NIHR Health Technology Assessment programme	Total ankle replacement versus ankle arthrodesis for patients aged 50–85 years with end-stage ankle osteoarthritis: the TARVA RCT
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Combination diagnostic tests offered as part of preventive health checks exams in overall population]
2023	NIHR Health Technology Assessment programme	Helping pregnant smokers quit: a multi-centre randomised controlled trial of electronic cigarettes versus nicotine replacement therapy
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Polymeric diet rich in TGF-β for inflammatory bowel disease in pediatric patients]
2023	NIHR Health Technology Assessment programme	Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis
2023	National Authority for Assessment and Accreditation in Healthcare (INEAS)	[Kadcyla® (trastuzumab emtansine) in the treatment of HER2-positive breast cancer : A rapid review]
2023	NIHR Public Health Research (PHR) programme	A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Triple-phase computed tomography in patients with liver lesion]
2023	NIHR Health Technology Assessment programme	Antidepressants in pregnancy: applying causal epidemiological methods to understand service-use outcomes in women and long-term neurodevelopmental outcomes in exposed children
2023	National Authority for Assessment and Accreditation in Healthcare (INEAS)	[Autologous adipose-derived stem cells for chronic wounds treatment : Full HTA report]
2023	NIHR Public Health Research (PHR) programme	Impact of a social prescribing intervention in North East England on adults with type 2 diabetes: the SPRING_NE multimethod study
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Dielectric radiofrequency for the treatment of primary hyperhidrosis and bromhidrosis]
2023	NIHR Health Technology Assessment programme	Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Transbronchial biopsy guided by endobronchial ultrasound (EBUS) in pathologies accesible by transbronchial puncture that required anatomopathological diagnosis]
2023	NIHR Health Services and Delivery Research programme	Understanding what affects psychological morbidity in informal carers when providing care at home for patients at the end of life: a systematic qualitative evidence synthesis
2023	The Danish Health Technology Council (DHTC)	[Assessment concerning glucose monitoring for the treatment of adult patients with type 1 diabetes]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Invasive electroencephalography for drug-resistant epilepsy]